Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.

Beigneux Y, Arnulf I, Guillaume-Jugnot P, Leu-Semenescu S, Maillart E, Lubetzki C, Benveniste O, Papeix C.

Mult Scler Relat Disord. 2019 Nov 25;38:101869. doi: 10.1016/j.msard.2019.101869. [Epub ahead of print]

PMID:
31785490
2.

Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.

Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, Labauge P.

Mult Scler Relat Disord. 2019 Nov;36:101406. doi: 10.1016/j.msard.2019.101406. Epub 2019 Sep 19.

PMID:
31563076
3.

Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients.

Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Le Guern G, Grunbaum S, Marignier R, Papeix C, Heron E, Gout O, Savatovsky J, Galanaud D, Vignal C, Touitou V, Deschamps R.

Eur J Neurol. 2020 Feb;27(2):384-391. doi: 10.1111/ene.14089. Epub 2019 Oct 20.

PMID:
31532865
4.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

5.

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.

Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Deschamps R, Solà-Valls N, Llufriu S, De Seze J, Blanco Y, Vukusic S, Saiz A, Marignier R.

J Neuroinflammation. 2019 Jul 2;16(1):134. doi: 10.1186/s12974-019-1525-1.

6.

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.

Mult Scler. 2019 May 31:1352458519849511. doi: 10.1177/1352458519849511. [Epub ahead of print]

PMID:
31148523
7.

Impact of an adaptive program for cognitive and emotional deficits (ADACOG program) in multiple sclerosis patients with cognitive impairments.

Pineau F, Socha J, Corvol JC, Louapre C, Assouad R, Maillart E, Lubetzki C, Papeix C.

Rev Neurol (Paris). 2019 May;175(5):305-312. doi: 10.1016/j.neurol.2018.08.008. Epub 2019 Mar 23.

PMID:
30910222
8.

Early radiological features of severe longitudinally extensive transverse myelitis over time.

Cattan S, Papeix C, Grabli D, Casez O, Shor N, Bustuchina Vlaicu M, Vicart S, Louapre C, Maillart E.

J Neurol Sci. 2019 May 15;400:7-9. doi: 10.1016/j.jns.2019.01.043. Epub 2019 Feb 4. No abstract available.

PMID:
30878638
9.

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL.

J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28.

10.

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):816. doi: 10.1007/s00415-019-09215-1.

PMID:
30759286
11.

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):806-815. doi: 10.1007/s00415-018-9160-9. Epub 2019 Jan 3. Erratum in: J Neurol. 2019 Feb 7;:.

PMID:
30607536
12.

False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.

Pourcher V, Todesco E, Dubois C, Pallier C, Lubetzki C, Louapre C, Papeix C, Maillart E.

Mult Scler. 2020 Feb;26(2):257-258. doi: 10.1177/1352458518818294. Epub 2018 Dec 11. No abstract available.

PMID:
30526282
13.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

14.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B.

Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3.

PMID:
29722639
15.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
16.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Review.

PMID:
29606320
17.

Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?

Maillart E, Lippi A, Lubetzki C, Louapre C, Papeix C.

Mult Scler Relat Disord. 2018 Feb;20:220-222. doi: 10.1016/j.msard.2018.02.004. Epub 2018 Feb 6.

PMID:
29433095
18.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
19.

Multiple sclerosis and aging.

Louapre C, Papeix C, Lubetzki C, Maillart E.

Geriatr Psychol Neuropsychiatr Vieil. 2017 Dec 1;15(4):402-408. doi: 10.1684/pnv.2017.0685. Review.

PMID:
29081400
20.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
21.

Fatigue evaluation in fingolimod treated patients: An observational study.

Masingue M, Debs R, Maillart E, Delvaux V, Lubetzki C, Vidal JS, Papeix C.

Mult Scler Relat Disord. 2017 May;14:8-11. doi: 10.1016/j.msard.2017.03.006. Epub 2017 Mar 14.

PMID:
28619437
22.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

23.

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center.

Roux T, Maillart E, Vidal JS, Tezenas du Montcel S, Lubetzki C, Papeix C.

Front Neurol. 2017 May 5;8:183. doi: 10.3389/fneur.2017.00183. eCollection 2017.

24.

Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?

Boudot de la Motte M, Louapre C, Bertrand A, Reach P, Lubetzki C, Papeix C, Maillart E.

Mult Scler. 2017 Apr;23(4):614-616. doi: 10.1177/1352458516682858. Epub 2016 Dec 14.

PMID:
28273764
25.

Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.

Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, Lubetzki C, Gouider R, Papeix C.

Neurology. 2017 Mar 28;88(13):1218-1225. doi: 10.1212/WNL.0000000000003762. Epub 2017 Feb 24.

PMID:
28235811
26.

Anxiety, emotional processing and depression in people with multiple sclerosis.

Gay MC, Bungener C, Thomas S, Vrignaud P, Thomas PW, Baker R, Montel S, Heinzlef O, Papeix C, Assouad R, Montreuil M.

BMC Neurol. 2017 Feb 23;17(1):43. doi: 10.1186/s12883-017-0803-8.

27.

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.

Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L; PGRx-AD Study Group.

J Autoimmun. 2017 May;79:84-90. doi: 10.1016/j.jaut.2017.01.005. Epub 2017 Feb 9.

28.

Can we discontinue disease-modifying treatments in multiple sclerosis patients? No.

Papeix C.

Rev Neurol (Paris). 2017 Jan - Feb;173(1-2):41-43. doi: 10.1016/j.neurol.2016.10.007. Epub 2016 Nov 30. No abstract available.

PMID:
27914654
29.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
30.

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

31.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
32.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

33.

Extensive and severe CNS demyelination associated with golimumab therapy.

Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C.

J Neurol. 2016 Sep;263(9):1869-71. doi: 10.1007/s00415-016-8238-5. Epub 2016 Jul 25. No abstract available.

PMID:
27456211
34.

Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - NO.

Papeix C, Lubetzki C.

Mult Scler. 2016 Aug;22(9):1128-30. doi: 10.1177/1352458516643397. Epub 2016 May 25. No abstract available.

PMID:
27225675
35.

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis.

Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dollé F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B.

Ann Neurol. 2016 May;79(5):726-738. doi: 10.1002/ana.24620.

36.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

37.

[Multisclerosis patient's support]

Maillart É, Papeix C.

Rev Prat. 2016 Jan;66(1):37-40. French.

PMID:
30512396
38.

Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.

Debs R, Maillart E, Fahed R, Papeix C, Duyckaerts C, Stadelmann C, Galanaud D, Lubetzki C.

Neurology. 2015 Nov 3;85(18):1630-2. doi: 10.1212/WNL.0000000000002084. Epub 2015 Oct 9. No abstract available.

PMID:
26453649
39.

Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study.

Papeix C, Gambotti L, Assouad R, Ewenczyck C, Tanguy ML, Pineau F, Houis MC, Mazevet D, Maillart E, Lubetzki C.

Mult Scler J Exp Transl Clin. 2015 Sep 28;1:2055217315608864. doi: 10.1177/2055217315608864. eCollection 2015 Jan-Dec.

40.

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP.

Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.

PMID:
26362900
41.

The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B.

Ann Neurol. 2015 Oct;78(4):554-67. doi: 10.1002/ana.24468. Epub 2015 Aug 21.

PMID:
26292991
42.

Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis.

Bayen E, Papeix C, Pradat-Diehl P, Lubetzki C, Joël ME.

Behav Neurol. 2015;2015:648415. doi: 10.1155/2015/648415. Epub 2015 May 20.

43.

High doses of biotin in chronic progressive multiple sclerosis: a pilot study.

Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A.

Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.

44.

Fecundity in women with multiple sclerosis: an observational mono-centric study.

Roux T, Courtillot C, Debs R, Touraine P, Lubetzki C, Papeix C.

J Neurol. 2015;262(4):957-60. doi: 10.1007/s00415-015-7663-1. Epub 2015 Feb 12.

PMID:
25673128
45.

Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?

Dubessy AL, Zujovic V, Papeix C, Stankoff B.

Rev Neurol (Paris). 2014 Dec;170(12):770-8. doi: 10.1016/j.neurol.2014.10.004. Epub 2014 Nov 6. Review.

PMID:
25459127
46.

Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.

Assouad R, Louapre C, Tourbah A, Papeix C, Galanaud D, Lubetzki C, Stankoff B.

Clin Neurol Neurosurg. 2014 Nov;126:55-63. doi: 10.1016/j.clineuro.2014.08.018. Epub 2014 Aug 20.

PMID:
25215443
47.

Cavitary pulmonary disease in a patient treated with natalizumab.

de Masson A, Maillart E, Veziris N, Meyssonnier V, Papeix C, Caumes E.

Presse Med. 2014 Sep;43(9):1009-12. doi: 10.1016/j.lpm.2013.12.012. Epub 2014 Apr 16. No abstract available.

PMID:
24742610
48.

Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study.

Louapre C, Perlbarg V, García-Lorenzo D, Urbanski M, Benali H, Assouad R, Galanaud D, Freeman L, Bodini B, Papeix C, Tourbah A, Lubetzki C, Lehéricy S, Stankoff B.

Hum Brain Mapp. 2014 Sep;35(9):4706-17. doi: 10.1002/hbm.22505. Epub 2014 Mar 31.

PMID:
24687771
49.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
50.

Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?

Maillart E, Louapre C, Lubetzki C, Papeix C.

Mult Scler. 2014 Apr;20(4):505-9. doi: 10.1177/1352458513516530. Epub 2013 Dec 23.

PMID:
24367037

Supplemental Content

Loading ...
Support Center